Related Experiment Video
Updated: Apr 12, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma
Sridevi Yadavilli1, Joseph Scafidi2, Oren J Becher3
1Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA.
Abstract:
Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis and are poorly understood brain cancers. Receptor tyrosine kinases stabilized by neuron-glial antigen 2 (NG2) protein are known to induce gliomagenesis. Here, we investigated NG2 expression in a cohort of DIPG specimens (n= 50). We demonstrate NG2 expression in the majority of DIPG specimens tested and determine that tumors harboring histone 3.3 mutation express the highest NG2 levels. We further demonstrate that microRNA 129-2 (miR129-2) is downregulated and hypermethylated in human DIPGs, resulting in the increased expression of NG2. Treatment with 5-Azacytidine, a methyltransferase inhibitor, results in NG2 downregulation in DIPG primary tumor cells in vitro. NG2 expression is altered (symmetric segregation) in mitotic human DIPG and mouse tumor cells. These mitotic cells co-express oligodendrocyte (Olig2) and astrocyte (glial fibrillary acidic protein, GFAP) markers, indicating lack of terminal differentiation. NG2 knockdown retards cellular migration in vitro, while NG2 expressing neurospheres are highly tumorigenic in vivo, resulting in rapid growth of pontine tumors. NG2 expression is targetable in vivo using miR129-2 indicating a potential avenue for therapeutic interventions. This data implicates NG2 as a molecule of interest in DIPGs especially those with H3.3 mutation.
Insights
Neuron-glial antigen 2 (NG2) is highly expressed in diffuse intrinsic pontine gliomas (DIPGs), particularly those with H3.3 mutations. Targeting NG2 with microRNA 129-2 shows therapeutic potential for these aggressive brain cancers.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Genetics
Background:
- Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors with poor outcomes.
- Receptor tyrosine kinases, stabilized by neuron-glial antigen 2 (NG2), are implicated in gliomagenesis.
- Understanding the molecular drivers of DIPG is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the role and expression of NG2 in diffuse intrinsic pontine gliomas (DIPGs).
- To explore the regulatory mechanisms of NG2 expression, including microRNA involvement.
- To assess the therapeutic potential of targeting NG2 in DIPGs.
Main Methods:
- Analysis of NG2 expression in 50 DIPG specimens.
- Assessment of microRNA 129-2 (miR129-2) levels and methylation status.
- In vitro studies using 5-Azacytidine treatment and NG2 knockdown.
- In vivo tumorigenicity assays of NG2-expressing neurospheres.
Main Results:
- NG2 is expressed in the majority of DIPG specimens, with highest levels in tumors harboring H3.3 mutations.
- microRNA 129-2 (miR129-2) is downregulated and hypermethylated in DIPGs, leading to increased NG2 expression.
- NG2 knockdown reduced cellular migration in vitro; NG2-expressing cells formed highly aggressive tumors in vivo.
- 5-Azacytidine treatment downregulated NG2 in DIPG cells; NG2 expression was linked to lack of terminal differentiation in mitotic cells.
Conclusions:
- NG2 is a significant molecule in DIPG pathogenesis, especially in H3.3-mutated tumors.
- Downregulation of miR129-2 and subsequent NG2 upregulation contribute to DIPG progression.
- Targeting NG2, potentially via miR129-2 restoration, represents a promising therapeutic strategy for DIPGs.
